Legislation roundup: Pharma monopoly and export, and data interface security risk monitoring

SAMR prohibits monopoly agreements that fix or modify pharmaceutical prices. Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC. Guidelines are provided for the methods of monitoring data interface security risks.

2 minute readAugust 16, 2024 at 07:15 AM

Susan Mok

Pharmaceuticals

State Administration for Market Regulation, Anti-Monopoly Guidelines for the Pharmaceuticals Sector (Draft for Comments)

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)